Actinic Keratosis

Table of Contents

  1. What Is Actinic Keratosis?
  2. Pathophysiology
  3. Risk Factors
  4. Clinical Presentation
  5. Diagnosis
  6. Treatment
  7. Prevention
  8. Prognosis and Follow-Up
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Is Actinic Keratosis?

Actinic keratosis (AK) is the most common precancerous skin lesion, affecting an estimated 58 million Americans. Also known as solar keratosis, it results from cumulative ultraviolet (UV) radiation causing DNA damage and keratinocyte dysplasia — abnormal squamous cell growth that remains confined to the epidermis. The term "senile keratosis" is now considered obsolete.

AK is best understood as squamous cell carcinoma (SCC) in situ of the epidermis, though its exact classification remains debated. Some authorities consider it a true precancer; others view it as an early form of SCC itself. Either way, the clinical imperative is the same: treat all AKs, because you cannot determine from appearance alone which lesion will progress.

The risk of an individual AK lesion progressing to invasive SCC ranges from approximately 0.1–10% per year per lesion (with some estimates as high as 16% in certain studies). Regression also occurs — AK is a dynamic lesion, not a static one. However, patients with AKs carry a 6- to 10-fold increased population risk of developing SCC compared with the general population.

A critical concept in understanding AK is field cancerization: UV-damaged skin harbors multiple pre-malignant clones scattered across a broad area. This explains why AKs tend to appear in clusters on chronically sun-exposed skin, and why new lesions continue to emerge even after visible lesions are treated. AKs do not arise in isolation — they are the visible tip of a large iceberg of subclinical UV-induced DNA damage in the surrounding skin.

AK affects primarily fair-skinned individuals and is most prevalent in Australia, where lifetime cumulative sun exposure is high. In adults over 70 in Australia, prevalence exceeds 80%. In the United States, AK prevalence is estimated at roughly 10% in people in their 40s, rising steadily with age.

Back to Table of Contents

Pathophysiology

The central pathological event in AK is ultraviolet-B (UVB) radiation-induced DNA damage. UVB creates cyclobutane pyrimidine dimers (CPDs) at dipyrimidine sites in DNA. When repair systems fail or are overwhelmed, these dimers lead to characteristic C→T and CC→TT transition mutations — the ultraviolet signature mutations that are the molecular fingerprint of UV-induced skin cancer.

TP53 Mutation — The Central Molecular Event

The most critical molecular alteration in AK is mutation of TP53, the gene encoding p53, the "guardian of the genome." TP53 mutations are present in more than 90% of SCCs and in many AKs. Normally, p53 detects DNA damage and either halts the cell cycle to allow repair or triggers apoptosis (programmed cell death). Mutant p53 loses this function, allowing keratinocytes with damaged DNA to survive, proliferate, and accumulate further mutations — the foundation of carcinogenesis.

Immunosuppression of Tumor Surveillance

Chronic UV exposure depletes Langerhans cells in the epidermis — the skin's resident immune sentinels. UV also induces local immunosuppression and promotes regulatory T cells (Tregs) that suppress anti-tumor immune surveillance. This mechanism explains the dramatically increased AK and SCC burden in immunosuppressed patients (organ transplant recipients, HIV-positive individuals, patients on long-term immunosuppressive therapy), where the immune "brakes" on abnormal keratinocyte growth are removed.

Additional Molecular Drivers

Beyond TP53, AK pathogenesis involves telomere dysfunction and chromosomal instability, RAS pathway activation, and upregulation of growth factor signaling. These accumulating genetic hits create the molecular foundation for progression from dysplastic keratinocytes (AK) to invasive SCC.

Histopathology

Under the microscope, AK shows keratinocyte atypia — enlarged, irregular nuclei with loss of normal polarity — confined to the epidermis. Other features include parakeratosis (retained nuclei in the stratum corneum), hyperkeratosis (thickened cornified layer), and solar elastosis in the dermis (basophilic degeneration of collagen = the UV signature in the deeper skin).

AK can be graded by severity: Grade I (mild dysplasia, focal involvement), Grade II (moderate dysplasia with acanthosis), and Grade III (severe or full-thickness dysplasia — Bowenoid AK — which closely approaches in situ SCC). The basement membrane remains intact in all grades; invasion through the basement membrane defines progression to invasive SCC.

Back to Table of Contents

Risk Factors

Ultraviolet Exposure

Cumulative lifetime UV exposure is the dominant risk factor for AK. Risk is elevated in outdoor occupations (farmers, ranchers, fishermen, construction workers, lifeguards), in geographic locations with high solar UV intensity (Australia, the American Southwest, equatorial regions), and in individuals with a history of tanning bed use. Tanning beds emit predominantly UVA, which penetrates deeper into the skin and also contributes to DNA damage and AK formation. Even intermittent intense UV exposure — particularly blistering sunburns in childhood — causes permanent DNA damage that can manifest as AK decades later.

Skin Phototype

Fair-skinned individuals bear the overwhelming burden of AK. Fitzpatrick Skin Type I (always burns, never tans) and Type II (usually burns, tans minimally) are at highest risk. Associated features — blue or green eyes, light hair, freckling, Northern European ancestry — each independently contribute. Darker skin types (IV–VI) are not immune, particularly under high cumulative UV exposure, but AK is substantially less common.

Immunosuppression

Immunosuppression dramatically amplifies AK risk. Solid organ transplant recipients — on calcineurin inhibitors, azathioprine, or mycophenolate — have AK prevalence of 40–80% within 5 years of transplant, and SCC becomes the most common malignancy in this group (rather than basal cell carcinoma, as in the general population). Other immunosuppressed groups at increased risk include patients with chronic lymphocytic leukemia (CLL), HIV infection, and those on long-term systemic corticosteroids or biologic immunosuppressants.

Age and Prior History

AK prevalence rises steeply with age as cumulative UV damage accumulates over decades. Prior AK and prior SCC are the strongest predictors of new AK development — patients who have had AK will continue to develop new lesions from the underlying UV-damaged field.

Other Risk Factors

Additional risk factors include arsenic exposure (arsenical keratoses, typically on palms and soles, distinct from UV-induced AK), ionizing radiation, xeroderma pigmentosum (a rare inherited DNA-repair deficiency causing AKs and SCCs in childhood), and male sex (historically reflecting greater occupational UV exposure, though this gap is narrowing with increased tanning bed use among women).

Back to Table of Contents

Clinical Presentation

Typical Appearance

The hallmark of AK is a rough, sandpaper-like texture on palpation. Early AK is often better felt than seen — a subtle roughness under the fingertip before any visible change is apparent. As the lesion develops, it appears as an erythematous (pink to red), scaly papule or patch, typically 2–6 mm, with poorly defined borders, on chronically sun-exposed skin. Common sites include the scalp (especially in bald or thin-haired men), face (forehead, temples, nose, cheeks, ears), dorsal forearms and hands, and lower legs in women.

Clinical Variants

Warning Signs of Progression to SCC

Features that raise concern for invasive SCC within or arising from an AK include: rapid growth, induration (hardness), ulceration, spontaneous bleeding, pain or tenderness, enlargement beyond 1 cm, and spreading erythema beyond the lesion border. Any AK with these features requires prompt biopsy.

Back to Table of Contents

Diagnosis

Clinical Diagnosis

Experienced dermatologists can diagnose AK clinically with a sensitivity of approximately 80%. The key clinical maneuver is gentle palpation — feeling for the characteristic rough, gritty texture on sun-damaged skin. Dermoscopy improves diagnostic accuracy and helps differentiate AK from other lesions.

Dermoscopy

Dermoscopic features of AK include:

Dermoscopy is particularly valuable for distinguishing AK from SCC (which shows more prominent vessels and structureless white areas) and from benign mimics such as seborrheic keratosis.

Biopsy Indications

Biopsy is indicated when: clinical diagnosis is uncertain; lesions are hyperkeratotic, indurated, ulcerated, or rapidly growing; lesions fail to respond to appropriate treatment; pigmented AK cannot be reliably distinguished from lentigo maligna; or actinic cheilitis is present. Histopathology confirms atypia confined to the epidermis without basement membrane invasion — invasion through the basement membrane defines invasive SCC.

Advanced Imaging

Reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) are non-invasive imaging modalities available at specialized centers that allow real-time cellular and depth imaging of AK, useful for monitoring treatment response and guiding biopsy decisions. Total body photography is valuable for tracking new AK development over time in high-risk patients.

Back to Table of Contents

Treatment

AK treatment falls into two broad categories: lesion-directed therapies that treat individual visible lesions, and field therapies that treat the entire UV-damaged area to address subclinical pre-malignant keratinocytes. Because field cancerization means subclinical AKs far outnumber visible ones, field therapy is generally preferred for patients with multiple lesions.

Lesion-Directed Therapies

Cryotherapy (liquid nitrogen) is the most commonly used in-office AK treatment. Liquid nitrogen at −196°C is applied for 5–30 seconds with a freeze-thaw cycle that selectively destroys dysplastic keratinocytes. It is suitable for isolated, well-defined lesions and produces immediate results. Risks include blistering, post-inflammatory hypopigmentation or hyperpigmentation (particularly in darker skin types), and pain. An adequate freeze requires a 2–3 mm margin around the lesion.

Curettage — physical scraping of the lesion with a curette, with or without electrodessication — is useful for thick or hyperkeratotic AKs. Shave excision with histopathologic examination is required for lesions suspicious for invasive SCC.

Field Therapies

5-Fluorouracil (5-FU) cream (Efudex 5%, Carac 0.5%, Tolak 4%) is the standard of care for AK field treatment. 5-FU is an antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis in rapidly dividing cells. A full-face course over 2–4 weeks produces intense inflammation, crusting, and erythema — this inflammatory response is the treatment working. A pulsed protocol (twice weekly for 6 weeks) is better tolerated. 5-FU demonstrates superior long-term AK clearance compared with other field therapies in randomized controlled trials, and it is inexpensive and widely available.

Imiquimod (Zyclara 3.75%, Aldara 5%) is a toll-like receptor 7 (TLR-7) agonist that activates innate and adaptive immune responses, driving apoptosis of atypical keratinocytes. A 16-week course applied 3 times per week is less irritating than 5-FU. It is moderately effective for immunocompetent patients.

Diclofenac gel (Solaraze 3%) inhibits COX-2 and arachidonic acid metabolism with anti-proliferative effects. Applied twice daily for 3 months, it is the mildest and best-tolerated field option with modest efficacy, suitable for thin or superficial AKs or patients who cannot tolerate more intensive regimens.

Tirbanibulin (Klisyri 1% ointment; FDA approved 2020) has a dual mechanism — inhibiting tubulin polymerization and Src kinase — and is applied once daily for only 5 days. In randomized controlled trials it showed non-inferiority to 5-FU 5% and offers an alternative for treatment-intolerant patients.

Photodynamic therapy (PDT) uses a topically applied photosensitizer — aminolevulinic acid (ALA) — that accumulates preferentially in AK cells as protoporphyrin IX. Activation by blue or red light generates singlet oxygen that selectively destroys the dysplastic cells. Daylight PDT, using natural sunlight as the activating source, is equally effective and substantially less painful than conventional office PDT with blue-light devices. PDT is excellent for facial and scalp field cancerization, producing durable clearance and cosmetically excellent results.

Laser resurfacing (ablative CO2 or erbium:YAG laser), chemical peels (trichloroacetic acid, phenol), and dermabrasion target the epidermis and upper dermis and are most effective for extensive facial field cancerization. All modalities resurface the entire UV-damaged field rather than targeting individual lesions.

Oral nicotinamide (vitamin B3, 500 mg twice daily) is the best-studied oral chemopreventive agent for AK and SCC. A landmark 2015 New England Journal of Medicine randomized controlled trial by Chen et al. demonstrated a 23% reduction in AK count over 12 months in high-risk patients. Nicotinamide is inexpensive, available over the counter, and safe. The benefit requires continued use and wanes after stopping.

Ingenol mebutate gel (Picato) was withdrawn from the European market in 2020 due to signals of increased SCC risk from randomized trials. It remains FDA-approved in the United States but is now rarely used given the safety concerns.

Back to Table of Contents

Prevention

Photoprotection

Daily broad-spectrum SPF 30+ sunscreen is the cornerstone of AK prevention. Broad-spectrum labeling indicates both UVA and UVB protection. Physical (mineral) blockers — zinc oxide and titanium dioxide — provide broad-spectrum protection without chemical absorption and are preferred for daily use. Sunscreen should be reapplied every 2 hours during outdoor exposure. An important misconception to address: SPF 100 is not twice as protective as SPF 50. SPF 50 blocks approximately 98% of UVB; SPF 100 blocks approximately 99%. The incremental difference is modest.

Protective Clothing and Behavior

UPF 50+ protective clothing, wide-brimmed hats (brim ≥3 inches), UV-protective sunglasses, and long-sleeved shirts provide physical UV barriers that sunscreen alone cannot replicate. Seeking shade during peak UV hours (10 a.m. to 4 p.m.) substantially reduces cumulative exposure. Tanning bed avoidance is essential — no cosmetic tan justifies the AK, SCC, and melanoma risk. An important nuance: standard window glass blocks UVB but transmits UVA, so daily facial exposure through car or office windows contributes to cumulative UV damage. A daily moisturizer with SPF is warranted even for individuals who work indoors.

Oral Chemoprevention

Nicotinamide 500 mg twice daily is particularly appropriate for patients with four or more AKs, or with a history of SCC, based on the Chen 2015 NEJM trial evidence. It is the only over-the-counter oral agent with randomized trial support for AK and skin cancer prevention.

Topical retinoids (tretinoin) promote normal keratinocyte differentiation and have modest AK preventive effects alongside photorejuvenation benefits. Oral acitretin (a systemic retinoid) significantly reduces AK and SCC burden in immunosuppressed organ transplant recipients, though it requires monitoring for liver toxicity, hyperlipidemia, and teratogenicity.

Special Populations: Organ Transplant Recipients

Transplant recipients require quarterly full-skin dermatology examinations, aggressive and early AK treatment with field therapies, and consideration of immunosuppression modification. Switching from calcineurin inhibitors (tacrolimus, cyclosporine) to mTOR inhibitors (sirolimus, everolimus) in consultation with the transplant team has been associated with reduced SCC incidence and should be discussed for patients developing significant AK burden or SCC.

Back to Table of Contents

Prognosis and Follow-Up

Natural History

Individual AK lesions have a heterogeneous natural history. Studies report that 15–53% of AKs spontaneously regress within 12 months, 12–25% persist unchanged, and 0.1–10% progress to invasive SCC per lesion per year. However, because patients typically carry multiple lesions simultaneously and develop new ones continually, the cumulative risk of SCC over a lifetime is substantial. Patients with AK carry a 6- to 10-fold increased population risk of developing SCC compared with people who have never had AK.

Field Cancerization and Recurrence

Recurrence after treatment is the rule, not the exception. The underlying UV-damaged field persists even after all visible AKs are cleared. New AKs will continue to emerge from subclinical pre-malignant clones in the surrounding skin. Patients should understand that AK management is an ongoing process, not a one-time cure. This counseling is essential for treatment adherence and realistic expectations.

Follow-Up Schedule

Reassessment 3–6 months after completing field therapy allows evaluation of treatment response, detection of residual or new AKs, and biopsy of any suspicious lesions. Patients with a history of multiple AKs or prior SCC should have dermatology visits every 3–6 months. Studies demonstrate that patients without regular dermatology follow-up have significantly higher SCC rates. Annual full-skin examinations are the minimum for all patients who have had AK.

Quality of Life During Treatment

Field therapies — particularly 5-FU and conventional PDT — cause significant erythema, pain, crusting, and temporary cosmetic changes during the treatment course. Patients should be counseled in advance: "it gets worse before it gets better — that reaction is the treatment working." The weeks of discomfort are the price of preventing skin cancer, and the long-term cosmetic outcome (removal of sun-damaged skin, improved texture and tone) is typically favorable.

Mortality Context

AK itself is not lethal. The mortality concern is progression to invasive cutaneous SCC. Cutaneous SCC causes approximately 15,000 deaths per year in the United States, more than melanoma in some analyses. AK management is fundamentally SCC prevention — the case for treating all AKs is a case for averting squamous cell carcinoma deaths.

Back to Table of Contents

Key Research Papers

PubMed topic search: Actinic Keratosis Treatment | Field Cancerization | AK Progression to SCC

Back to Table of Contents

Connections

Back to Table of Contents